Definium Therapeutics, Inc. (DFTX)
Healthcare
Biotechnology
—
43.50 $
-2.2%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Definium Therapeutics, Inc. (DFTX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 80.7% of the shares are freely tradable; institutional investors hold 65.6%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
65.6%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
1.2%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
80.7%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
9.8%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
133Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BlackRock Inc | 7.78 | 8,480,230 | +2.5 | 03/31/2026 |
| Driehaus Capital Management LLC | 5.42 | 5,911,889 | -9.6 | 03/31/2026 |
| venBio Select Advisor LLC | 4.58 | 5,000,000 | +0.0 | 03/31/2026 |
| HHG PLC | 3.26 | 3,556,041 | +47.4 | 03/31/2026 |
| Deep Track Capital, LP | 2.75 | 3,000,000 | +78.9 | 03/31/2026 |
| Vanguard Group Inc | 2.38 | 2,591,901 | +28.8 | 12/31/2025 |
| Geode Capital Management, LLC | 2.29 | 2,495,399 | +7.0 | 03/31/2026 |
| State Street Corp | 2.27 | 2,471,873 | +4.4 | 03/31/2026 |
| Octagon Capital Advisors LP | 2.24 | 2,440,000 | +9.4 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| iShares Russell 2000 ETF | 2.17 | 2,365,046 | +0.9 | 05/29/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.